Abivax names four commercial leaders ahead of planned NDA filing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments
July 23, 2026 4:05 PM EDTAbivax Strengthens Commercial Capabilities With Strategic Leadership Appointments
Appointed industry leaders bring decades of experience across commercial strategy, patient services, launch readiness, and field force development
PARIS, France July 23, 2026 10:05 p.m. CEST Abivax SA (Euronext Paris: FR0012333284 ABVX / Nasdaq: ABVX) (Abivax or the Company), a clinical-stage biotechnology company focused on developing therapeutics that harness the bodys natural regulatory mechanisms to stabilize the immune response in... More
